We live in a world increasingly marred by toxicants that can affect virtually every organ and system in our bodies.

 

Most forms of cancer and nervous system degeneration have been linked to toxicant exposure by an increasing body of scientific studies. Despite this accumulating evidence, our understanding of precisely how and which agents cause certain diseases, and how to mitigate their effects, remains in its infancy. The key resides in choosing the right research and development pathways toward eliminating the xenobiotic responsible for these devastating disorders. By virtue of top-notch biomedical research and innovation expertise, Cancer Research and Biotechnology AG will bring forth a long-awaited solution.

The Cancer Research and Biotechnology AG team has researched and accumulated data (published and unpublished), pointing to an essential factor that causes lethal human cancers and contributes eg. to the pathogenesis of brain degeneration. This factor behaves as an initiator and promoter of disease processes, thus acting very upstream in cancer generation and progression pathway. Based on this recognition, Cancer Research and Biotechnology AG is developing proprietary therapeutic strategies aimed at, first, shielding the body, and second, eliminating the harmful effects, thus reducing the risk of disease initiation and progression at an early stage.

We live in a world increasingly marred by toxicants that can affect virtually every organ and system in our bodies.

 

Most forms of cancer and nervous system degeneration have been linked to toxicant exposure by an increasing body of scientific studies. Despite this accumulating evidence, our understanding of precisely how and which agents cause certain diseases, and how to mitigate their effects, remains in its infancy.  The key resides in choosing the right research and development pathways toward eliminating the xenobiotic responsible for these devastating disorders. By virtue of top-notch biomedical research and innovation expertise, Cancer Research and Biotechnology AG will bring forth a long-awaited solution.

The Cancer Research and Biotechnology AG team has researched and accumulated data (published and unpublished), pointing to an essential factor that causes lethal human cancers and contributes to the pathogenesis of brain degeneration. This ubiquitous, insidiously acting toxicant behaves as an initiator and promoter of disease processes, thus acting very upstream in cancer generation and progression pathway. Cancer Research and Biotechnology AG is spearheading the recognition of the widespread deleterious effects of this agent. This constitutes the first step in bringing an effective curative and protective method to millions of present and potential patients. Based on this recognition, Cancer Research and Biotechnology AG is developing proprietary therapeutic strategies aimed at, first, shielding the body against the harmful actions of this agent, and second, eliminating its effects. We believe this protective effect could eventually also be applicable to infants as well, thus reducing the risk of disease initiation and progression at an early stage.